Chemoresistance is a major issue in medical oncology. A large number of cancer patient deaths result from resistance acquired during treatments. Along with resistance conventional chemotherapeutics drugs also showed toxicity to normal cells which may require treatment interruption. Phytochemicals may offer alternatives to circumvent the development of resistance while sparing healthy tissues. However, their use is limited because of their low solubility and limited half-life. This is why Phytonanotechnology is currently emerging to make phytochemicals more prone to be delivered to cancer cells upon nanovehicle surface functionalization or conjugation with tumor-targeting entities. Nano-formulations may include micelles, liposomes and nanoparticles which all have the potential to be loaded with high amounts of phytochemicals, including poorly stable and weakly soluble ones. The final goal is double: (i) increase in local tumor bioavailability of phytochemicals and (ii) reduction in potential adverse side effects to the nearby/distant organs.
This Research Topic welcomes submissions covering the following themes but not limited to:
1. New development in nano-delivery of anticancer phytochemicals
2. Challenges associated with the in vivo use of nanocarriers
3. How phytonanoformulation may reduce resistance and tumor relapse?
4. How phytonanoformulation may reduce toxicity?
Important Note: Extracts will be considered if at least one active compound has been detected and quantified. Anti-cancer modalities of natural products demonstrated using in vitro models must be supported in at least two well-authenticated cancer cell lines (ideally originating from distinct organs/tissues).
Chemoresistance is a major issue in medical oncology. A large number of cancer patient deaths result from resistance acquired during treatments. Along with resistance conventional chemotherapeutics drugs also showed toxicity to normal cells which may require treatment interruption. Phytochemicals may offer alternatives to circumvent the development of resistance while sparing healthy tissues. However, their use is limited because of their low solubility and limited half-life. This is why Phytonanotechnology is currently emerging to make phytochemicals more prone to be delivered to cancer cells upon nanovehicle surface functionalization or conjugation with tumor-targeting entities. Nano-formulations may include micelles, liposomes and nanoparticles which all have the potential to be loaded with high amounts of phytochemicals, including poorly stable and weakly soluble ones. The final goal is double: (i) increase in local tumor bioavailability of phytochemicals and (ii) reduction in potential adverse side effects to the nearby/distant organs.
This Research Topic welcomes submissions covering the following themes but not limited to:
1. New development in nano-delivery of anticancer phytochemicals
2. Challenges associated with the in vivo use of nanocarriers
3. How phytonanoformulation may reduce resistance and tumor relapse?
4. How phytonanoformulation may reduce toxicity?
Important Note: Extracts will be considered if at least one active compound has been detected and quantified. Anti-cancer modalities of natural products demonstrated using in vitro models must be supported in at least two well-authenticated cancer cell lines (ideally originating from distinct organs/tissues).